Discovery Engines for Antibodies, Peptides, and Ligands
Introduction: Unlocking the Power of Display
Biopharma discovery pipelines thrive on one universal principle: the ability to generate binders—molecules that recognize and interact with specific targets with precision. From therapeutic antibodies that neutralize pathogens or block signaling pathways, to peptide ligands that modulate receptor activity, to engineered proteins that unlock diagnostic specificity, the future of medicine depends on discovering molecules that bind with accuracy and affinity.
Among all technologies developed for this purpose, phage display remains one of the most versatile and proven platforms. Since its invention, phage display has led to dozens of FDA-approved drugs and diagnostics, and it continues to fuel the pipelines of global pharma and emerging biotech alike. By coupling molecular diversity with high-throughput selection, phage display transforms the natural process of evolution into an engineered, directed discovery engine.
At Phage Biologics, we specialize in phage display not as a side capability but as a dedicated platform, fully integrated into our microbial and phage-first CDMO model. We empower clients to construct, screen, and scale biomolecule libraries with unrivaled efficiency and depth. Whether your goal is a therapeutic monoclonal antibody, a diagnostic peptide, or a protein binder for a novel target, our phage display services provide the infrastructure, expertise, and scalability to transform discovery into product reality.
Filamentous Phage Expression & Library Construction
Our Focus on M13 and f1 Filamentous Phages
Phage display relies on the ability to fuse foreign peptides or proteins to viral coat proteins, presenting them externally while maintaining phage infectivity. The filamentous phages M13 and f1 remain the gold standard for display because of their robustness, scalability, and capacity to present diverse libraries.
Capabilities We Offer
- Custom Library Design – Tailored peptide and protein-coding libraries designed to maximize diversity and coverage, with degenerate codon strategies minimizing stop codons and bias.
- Antibody Library Construction – scFv, Fab, and VHH (nanobody) formats, engineered into phagemid systems to enable efficient display and recovery.
- Synthetic & Natural Sources – Incorporation of immune repertoires from immunized hosts or fully synthetic, in silico–optimized sequences.
- Library Scale – Libraries ranging from 10⁷ to >10¹¹ independent clones, depending on client needs and target class.
Why It Matters
The strength of a phage display campaign is proportional to the diversity and integrity of its starting library. Our tailored construction strategies ensure clients begin discovery with the broadest possible solution space.
Peptide, Antibody & Protein Display Systems
Phage display is not one-size-fits-all. Different therapeutic and diagnostic modalities demand different display strategies.
Peptide Display
- Short Peptide Libraries – Focused diversity, often 7–12 residues, ideal for epitope mapping and motif discovery.
- Cyclic Peptides – Engineered for conformational stability and high-affinity receptor binding.
- Linear Peptides – Rapid discovery of binders to exposed protein surfaces or linear epitopes.
Antibody Display
- scFv Libraries – Compact antibody fragments ideal for discovery campaigns with downstream engineering.
- Fab Libraries – Higher fidelity to full antibody structure, suited for therapeutic development.
- VHH/Nanobody Libraries – Single-domain antibodies derived from camelids, with exceptional tissue penetration and stability.
Protein & Ligand Display
- Protein Scaffolds – Display of engineered proteins such as DARPins or alternative scaffolds.
- Ligand Libraries – Designed for receptor binding, cofactor interactions, and diagnostic applications.
Why It Matters
The ability to adapt display systems to modality needs is essential for efficient downstream translation. Our platform accommodates the full range of discovery campaigns, from rapid peptide mapping to clinical-grade antibody development.
Screening & Selection Workflows
Library construction is only half the story—success depends on the ability to screen and select binders with precision.
Our Approach
- Biopanning – Iterative rounds of binding, washing, and elution refine libraries toward high-affinity, target-specific binders.
- Solid-Phase & Solution-Phase Assays – Target presentation in formats that reflect physiological context, reducing false positives.
- Negative Selection – Removal of off-target binders through subtractive panning against irrelevant proteins or control surfaces.
- Stringency Tuning – Progressive tightening of binding and washing conditions to enrich for the strongest candidates.
- Automation – Robotic liquid handling systems accelerate rounds of selection while ensuring reproducibility.
Analytical Validation
- Binding Kinetics – SPR (surface plasmon resonance) and BLI (bio-layer interferometry) provide kinetic constants (kon, koff, KD).
- Epitope Mapping – Determination of binding epitopes to guide therapeutic development and intellectual property positioning.
- Next-Gen Sequencing Integration – Deep sequencing of enriched pools identifies dominant clones early, guiding downstream validation.
Why It Matters
The quality of screening determines the clinical viability of candidates. Our advanced, iterative workflows ensure only the highest-affinity, most specific binders advance.
Scale-Up of Validated Binders
Discovery is the beginning, not the end. Once validated binders emerge, scale-up and characterization are required for therapeutic or diagnostic use.
Scale-Up Capabilities
- Clonal Expansion – Isolation of individual phage clones followed by high-yield amplification.
- Protein Expression Systems – Transition of phage-derived sequences into bacterial, yeast, or mammalian expression systems.
- Purification – Chromatographic purification of antibodies, peptides, or proteins to research- and GMP-grade standards.
- Formulation Support – Early formulation strategies for stability, solubility, and delivery optimization.
Preclinical Readiness
- In Vitro Functional Assays – Activity validation in cell-based systems.
- Animal Studies Support – Supplying preclinical quantities of binders for pharmacology, efficacy, and toxicity studies.
Why It Matters
Our ability to transition seamlessly from phage-discovered binder to scalable therapeutic-grade molecule is what sets Phage Biologics apart from academic discovery groups and generalist CDMOs.
QC & Analytical Infrastructure
Analytical rigor underpins credibility in discovery campaigns.
Core Assays
- Affinity Characterization – SPR, BLI, and ELISA-based binding assays.
- Functional Potency – Cell-based assays, receptor-ligand interaction assays.
- Stability Testing – Thermal shift assays, freeze-thaw tolerance, long-term storage conditions.
- Genetic Verification – Sanger and NGS sequencing confirm integrity of displayed constructs.
- Safety & Purity – Endotoxin testing and contaminant removal prior to downstream use.
Why It Matters
Comprehensive analytics ensure that candidates identified through phage display stand up to regulatory scrutiny and clinical translation.
Regulatory & IP Alignment
Phage display is a discovery engine, but its output must survive the realities of regulatory science and intellectual property.
Regulatory Considerations
- Data Packages – Generation of IND/IMPD-enabling datasets that document discovery workflows, library integrity, and analytical results.
- CMC Alignment – Transition of binder sequences into GMP-compliant expression systems.
- Comparability Studies – Ensuring consistency across libraries, batches, and formats.
Intellectual Property
- Freedom to Operate – Sequence verification and novelty analysis.
- Patent Strategy Support – Structuring discovery campaigns to maximize IP claims on unique binders and epitopes.
Why It Matters
Discovery without regulatory and IP foresight risks derailment. Our platform integrates both from the outset, ensuring clients maintain clear paths to approval and commercialization.
GMP-Readiness & Clinical Translation
While phage display itself is a research-stage tool, the molecules it discovers must ultimately be produced under GMP for clinical use.
Our GMP Integration
- Tech Transfer Pathways – Seamless transfer of validated sequences into our microbial fermentation or mammalian expression units.
- Scale Flexibility – From milligram quantities for early studies to multi-gram GMP lots for Phase I/II trials.
- Fill-Finish Support – Aseptic vialing and formulation for clinical material.
Why It Matters
Most discovery CROs stop at the binder. We take candidates all the way to clinical readiness, eliminating handoff risks and accelerating time to clinic.
Integrated Continuum: Discovery to Development
The hallmark of Phage Biologics is our ability to deliver continuity.
- One Platform, Full Journey – Library construction, screening, selection, and scale-up under one roof.
- Reduced Risk – No reliance on fragmented providers; our in-house model minimizes variability.
- Tailored Engagements – Modular services that match your program stage, from exploratory peptide mapping to Phase I-ready antibody supply.
Why Choose Phage Biologics for Phage Display
- Niche Expertise – We are not a generalist CRO; we are a phage-first CDMO with dedicated focus on display technologies.
- Library Depth – Capable of generating libraries up to 10¹¹ clones, designed for maximum diversity.
- Selection Rigor – Advanced screening workflows integrating robotics, NGS, and biophysics.
- Downstream Integration – From discovery to GMP-ready molecules, eliminating costly handoffs.
- Global Alignment – Regulatory and IP foresight ensures discoveries translate to clinical and commercial impact.
Conclusion: Building Tomorrow’s Biologics
The promise of modern medicine lies in precision molecules that bind with power, selectivity, and therapeutic impact. Phage display remains the premier engine of discovery, fueling pipelines for antibodies, peptides, and protein ligands that will define the next era of therapy and diagnostics.
At Phage Biologics, we are proud to be a dedicated CDMO for phage display. Every system, every library, every screening protocol has been designed with discovery translation in mind. That focus allows us to deliver not just binders, but future therapeutics.
Whether you are mapping epitopes, hunting for diagnostic ligands, or advancing antibody leads into the clinic, our platform offers a comprehensive, specialized, and globally aligned solution.
Together, we will discover the binders that power the therapies of tomorrow.
Contact our team today at info@phagebiologics.com